CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine
| Autor: | A Sietmann, Els W. Boeschoten, G. Offermann, F Friedrichs, Reinhold Kreutz, Silke Kain, Friedo W. Dekker, Peter Martus, Joachim Beige, Monika Stoll, F van der Sman-de Beer, Juliane Bolbrinker |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Genotype Gastroenterology Cohort Studies Maintenance therapy Internal medicine Genetics medicine Cytochrome P-450 CYP3A Humans Kidney transplantation Survival analysis Pharmacology Kidney Proportional hazards model business.industry Hazard ratio medicine.disease Kidney Transplantation Survival Analysis medicine.anatomical_structure Cohort Cyclosporine Molecular Medicine business Immunosuppressive Agents Cohort study |
| Zdroj: | The Pharmacogenomics Journal. 8:416-422 |
| ISSN: | 1473-1150 1470-269X |
| Popis: | The CYP3A5*1 allele has been linked to high expression of CYP3A5 and metabolism of cyclosporine. We evaluated the role of CYP3A5*1 for long-term survival in renal transplant patients in a cohort of 399 patients who underwent cadaveric or living donor kidney allograft transplantation. All patients were treated with a similar cyclosporine-based immunosuppressive maintenance therapy protocol. The mean duration of follow-up was 8.6+/-3.7 years. In univariate survival analysis, the presence of the CYP3A5*1 allele in recipients significantly increased patient survival P=0.028 (log-rank), resulting in a hazard ratio (HR) of 0.52 (95% CI=0.29-0.94). When the presence of the CYP3A5*1 allele was included in multivariate Cox regression analyses accounting for major risk factors for patient death, CYP3A5*1 still conferred a protective effect. Further, haplotype analysis at the CYP3A5 locus confirmed that CYP3A5*1 might indeed be responsible for this survival benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|